David A. Siegel Longeveron Inc. Transaction History

Two Sigma Advisers, LP

  • $42.5 Billion
  • Q1 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 15, 2021
SELL
$3.4 - $8.3 $177,140 - $432,430
-52,100 Closed
0 $0
Q2 2021

Aug 16, 2021
BUY
$5.2 - $8.13 $194,480 - $304,062
37,400 Added 254.42%
52,100 $424,000
Q1 2021

May 17, 2021
BUY
$5.66 - $8.45 $83,202 - $124,214
14,700 New
14,700 $97,000

About Longeveron Inc.

LGVN Quotes by TradingView
  • Ticker LGVN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 5,925,940
  • Market Cap $9.96M
  • Description
  • Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult ...
More about LGVN
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email